Comparative Pharmacology
Head-to-head clinical analysis: MOBAN versus MOLINDONE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOBAN versus MOLINDONE HYDROCHLORIDE.
MOBAN vs MOLINDONE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MOBAN (molindone) is an antipsychotic agent with mechanism of action not fully defined, but believed to involve dopamine D2 receptor blockade in the mesolimbic system, with minimal extrapyramidal effects due to weak D2 binding and possible serotonergic modulation.
Dopamine D2 receptor antagonist; also blocks serotonin 5-HT2A receptors and alpha-adrenergic receptors.
Oral: 50-100 mg/day in 3-4 divided doses, increase to 225 mg/day for severe conditions; maximum 400 mg/day. IM: 50-100 mg every 4-6 hours; maximum 400 mg/day.
50-225 mg/day orally in 3-4 divided doses; usual effective dose 50-75 mg/day; maximum 225 mg/day.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours for parent drug; active metabolite (molindone) half-life ~12-15 hours; steady-state reached in 2-3 days.
1.5-2 hours; shorter than typical antipsychotics, requiring multiple daily dosing.
Renal: 70-80% as metabolites and unchanged drug; biliary/fecal: ~20%.
Renal: 65-70% as metabolites and unchanged drug; Fecal: 20-25%; Biliary: minor.
Category C
Category C
Antipsychotic
Antipsychotic